David Lamond, Director at Quince Therapeutics, Inc. (QNCX), bought 475,234 shares at $1.32 ($620K) on 2023-08-15, disclosed to the SEC on 2023-08-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.32 | 107,886 | $142K | 23.0% |
| 2 | $1.32 | 107,886 | $142K | 23.0% |
| 3 | $1.29 | 117,348 | $151K | 24.4% |
| 4 | $1.29 | 117,348 | $151K | 24.4% |
| 5 | $1.29 | 24,766 | $32K | 5.2% |
| Total | $1.30 avg | 475,234 |
| $620K |
| 100% |
| Filing → |
| QNCX | BUY | 2023-12-01 | $41K | — | Filing → |
| QNCX | BUY | 2023-08-31 | $216K | — | Filing → |
| AMTI | BUY | 2022-05-23 | $211K | — | Filing → |